Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
about
Tubulin-interactive natural products as anticancer agentsStructural insight into the inhibition of tubulin by vinca domain peptide ligandsAxonal Transport and Neurodegeneration: How Marine Drugs Can Be Used for the Development of TherapeuticsStructural Basis of Microtubule Destabilization by Potent Auristatin Anti-MitoticsIn vitro activities and postantifungal effects of the potent dolastatin 10 derivative auristatin PHE.Specific activities of dolastatin 10 and peptide derivatives against Cryptococcus neoformansAntitumor peptides from marine organismsPhase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.Impact of marine drugs on cytoskeleton-mediated reproductive eventsMechanism targeted discovery of antitumor marine natural products.A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugsInteractions of halichondrin B and eribulin with tubulin.Drugs that target dynamic microtubules: a new molecular perspectiveImmunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.Differential gene expression in auristatin PHE-treated Cryptococcus neoformansConformation-activity relationships of polyketide natural products.Antineoplastic agents. 515. Synthesis of human cancer cell growth inhibitors derived from 3,4-methylenedioxy-5,4'-dimethoxy-3'-amino-Z-stilbeneInteraction of pseudolaric acid B with the colchicine site of tubulin.Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agentsStrategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.Intracellular activation and deactivation of tasidotin, an analog of dolastatin 15: correlation with cytotoxicityDemonstration of microtubule-like structures formed with (-)-rhazinilam from purified tubulin outside of cells and a simple tubulin-based assay for evaluation of analog activity.Microtubule dynamics as a target in oncology.Targeting microtubules by natural agents for cancer therapy.Design, synthesis, and biological evaluation of diminutive forms of (+)-spongistatin 1: lessons learned.An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2.Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: ecteinascidin 743, isohomohalichondrin-B and LL-15.Anti-microtubule activity of tubeimoside I and its colchicine binding site of tubulin.Biomimetic Synthesis of Cbz-(S)-Dolaphenine.The PN2-3 domain of centrosomal P4.1-associated protein implements a novel mechanism for tubulin sequestrationAntiproliferative Activity of Crocin Involves Targeting of Microtubules in Breast Cancer CellsDivalent cation and ionic strength effects on Vinca alkaloid-induced tubulin self-association.Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications.Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.
P2860
Q24650163-2568DDE3-E7E6-4238-97E2-AC334DE86C83Q27652119-AA5D03A7-06B0-4CA6-8C51-2C93091E83B8Q28079729-EA053BEF-2C77-480A-8C10-2A854A0BA39AQ28553497-32D10F70-423C-4652-A93E-E6B4D6A5054DQ30453646-14B3878A-BB02-4C23-97F8-2E883BD4A77EQ30453670-5DF7A0D5-07C1-4E04-A050-989C2EF0F6FEQ31040702-1D5C126D-7055-4047-B1D8-5741277020B3Q33495209-5D9D2101-A6FD-4719-A45F-E8A396F2F9D1Q33836958-DE7B829A-A4D3-4F2D-B63E-E71DCE88B5ABQ34012630-A5BDFEF4-87D6-417D-8F94-43E931190F0FQ34281123-6FD249B1-E814-49BC-AF94-913FA409D44EQ35088820-53BE4DA0-8C76-4623-B3B9-FDA58C2B2B6CQ35163252-3ACC56A3-0213-448D-9280-8820293A01C5Q35459059-A385DC64-0CAD-4D61-9B22-A84573461494Q35547462-693ACE1E-5DAC-4AC6-ADB8-5A7376B6977DQ35645437-AC4B1908-5847-4084-BA2B-0BF8314C8FA0Q35909593-A71D6884-00E6-4CC3-95CB-739056C7397CQ36110135-40E5AFFD-3621-4268-A09E-7A4538AC5DFBQ36291976-8652DA8B-81CE-40AA-8EFF-CCEC45519ADFQ36372894-5E3B99A0-AAD4-49DC-BC19-9DA37A399A44Q36742259-7F222488-80FD-4E1F-B7D9-62DA0500A53CQ37083120-8FCD2D83-D5AA-49B5-A4AF-08E3ED2E9F20Q37304620-D80B5DAE-F089-49D8-A843-A994780BA5BCQ37360708-4F5B114C-FED5-49E6-A97D-DD340A2785DBQ37623838-F4F6EEAE-655A-4DE2-B77C-24BC9CCF6401Q38279846-6CFD032F-4245-43F8-A114-E0DA4F3D31F8Q39298392-9900CC8F-CFC3-480D-9F22-FB9A157B3D9CQ40024877-163BEDA0-7A4E-441E-B69D-E79C2E00D40DQ40046819-1EA9B0B7-2C0D-417B-BCB2-C4CC82C8B7A1Q41511870-0146A223-FB4B-4663-B451-053D487BB169Q41811565-BBED093A-672F-4DCD-BC7A-05D6A29F9103Q41843503-94214CEC-7C89-44BC-9D21-8DEE1F5017C7Q42933523-7F0BC544-8254-455A-B16D-45253E9D57CBQ48773255-F1D9CE0D-74D5-472E-856B-295ABB8CC923Q52593621-45105E71-1FF2-4994-BCA0-6C12A6B694D0Q54974194-5EC62E6C-FEE9-4BE4-B24F-39B14E05AD03
P2860
Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh
1990年學術文章
@zh-hant
name
Binding of dolastatin 10 to tu ...... tide and vinca alkaloid sites.
@en
Binding of dolastatin 10 to tu ...... tide and vinca alkaloid sites.
@nl
type
label
Binding of dolastatin 10 to tu ...... tide and vinca alkaloid sites.
@en
Binding of dolastatin 10 to tu ...... tide and vinca alkaloid sites.
@nl
prefLabel
Binding of dolastatin 10 to tu ...... tide and vinca alkaloid sites.
@en
Binding of dolastatin 10 to tu ...... tide and vinca alkaloid sites.
@nl
P2093
P1476
Binding of dolastatin 10 to tu ...... tide and vinca alkaloid sites.
@en
P2093
P304
17141-17149
P407
P577
1990-10-01T00:00:00Z